Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sun-pharmaceutical-industries-limited" target="_blank" data-smartkarma-citation="entities:98:1" rel="noopener">Sun Pharmaceutical Industries (SUNP IN)</a> is acquiring <a href="https://www.smartkarma.com/entities/organon-co" target="_blank" data-smartkarma-citation="entities:36829:1" rel="noopener">Organon &amp; (OGN US)</a> for $14 per share in an all‑cash transaction, representing an equity valuation of $4B and enterprise valuation of ~$12B.</li>
<li>Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction is expected to close in early 2027.</li>
<li>Organon acquisition is aligned with Sun Pharma’s strategy of growing its innovative medicines business. Innovative medicine will have a 27% revenue share in the combined entity, up from 20% now.</li>
</ul>



Sun Pharmaceutical Industries (SUNP IN) is acquiring Organon &amp; (OGN US) for $14 per share in an all‑cash transaction, representing an equity valuation of $4B and enterprise valuation of ~$12B.
Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction is expected to close in early 2027.
Organon acquisition is aligned with Sun Pharma’s strategy of growing its innovative medicines business. Innovative medicine will have a 27% revenue share in the combined entity, up from 20% now.


Sun Pharmaceutical (SUNP IN): Organon Acquisition to Enhance Scale At the Cost of Growth